AtheroNova starts AHRO-001 Stage 1 clinical trial for treatment of atherosclerosis AtheroNova Inc http://cialisosterreich.com/generika-oder-original/ ., a biotech firm focused on the study and development of substances to securely regress atherosclerotic plaque and improve lipid profiles in human beings, today announces accomplishment of a significant milestone with the initiation of a Stage 1 clinical trial using its lead substance, AHRO-001. The clinical study has been executed in Russia with AtheroNova's licensing partner, OOO CardioNova.